Outcome comparison of pyrotinib with current standard of care in the second/third line setting in advanced non-small cell lung cancer patients with HER2 mutation.
- Author:
Shiqi MAO
1
;
Libo LUO
1
;
Shuo YANG
1
;
Yan WANG
1
;
Fei ZHOU
1
;
Jia YU
1
;
Bin CHEN
1
;
Guanghui GAO
1
;
Xuefei LI
2
;
Chao ZHAO
2
;
Lei CHENG
2
;
Yiwei LIU
1
;
Wanying WANG
1
;
Keyi JIA
1
;
Chuchu SHAO
1
;
Xinyu LIU
1
;
Xiaoxia CHEN
1
;
Chunxia SU
1
;
Caicun ZHOU
1
;
Fengying WU
1
;
Shengxiang REN
1
Author Information
- Publication Type:Journal Article
- MeSH: Humans; Aminoquinolines/therapeutic use*; Carcinoma, Non-Small-Cell Lung/genetics*; Lung Neoplasms/genetics*; Mutation/genetics*; Standard of Care
- From: Chinese Medical Journal 2023;136(7):848-850
- CountryChina
- Language:English
